
In this episode of The BioHub by Avetix, I'm joined by Samir Ounzain, CEO and Co-Founder of HAYA Therapeutics.Samir shares the journey from pioneering research into the so-called "dark genome" to building one of biotech's most exciting RNA therapeutics companies. We discuss why long non-coding RNAs could unlock an entirely new class of precision medicines, the challenge of turning groundbreaking science into a business, and how HAYA is approaching diseases with significant unmet need.We also explore the importance of resilience in biotech, the evolution from scientist to CEO, the role AI is beginning to play in drug discovery, and what the future holds for RNA therapeutics and precision medicine.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Episode 206 - Valerie Vanhooren - CEO & Co-Founder Ona Therapeutics

Episode 205 - Paul Bresge - CEO of Ray Therapeutics

Episode 203 - Tim Noyes - CEO of Newleos Therapeutics

Episode 202 - Ben Swanson - CEO of Skeletalis
Free AI-powered recaps of The BioHub - by Avetix and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.